Navigation

Psoriatic arthritis - golimumab

Golimumab for the treatment of psoriatic arthritis

Status: History
Expected date of issue: April 2011
Referral date: November 2008
Process: STA
Topic area:
  • Musculoskeletal
 

NICE project team

Executive Lead: Andrew Dillon
Technical Lead: Whitney Miller
Communications manager: Tonya Gillis
Project manager: Lori Farrar
Top


 

Provisional schedule

Closing date for invited submissions / evidence submission: 15 June 2010
1st appraisal committee meeting: 08 September 2010
2nd appraisal committee meeting 10 November 2010
Top


 

Consultees and commentators

Consultees Commentators (no right to submit or appeal)

Manufacturers/sponsors

  • Centocor/Schering-Plough (golimumab)

Patient/carer groups

  • Psoriasis and Psoriatic Arthritis Alliance
  • Psoriasis Association

Professional groups

  • British Association of Dermatologists
  • British Health Professionals in Rheumatology
  • British Society for Rheumatology
  • Primary Care Rheumatology Society
  • Royal College of Nursing
  • Royal College of Pathologists
  • Royal College of Physicians

Others

  • Department of Health
  • NHS Haringey
  • NHS Havering
  • Welsh Assembly Government

General

  • British National Formulary
  • Commissioning Support Appraisals Service
  • Department of Health, Social Services and Public Safety for Northern Ireland
  • NHS Quality Improvement Scotland

Comparator manufacturer(s)

  • Abbott (adalimumab)
  • Pfizer (methotrexate, sulfasalazine)
  • Sanofi-Aventis (leflunomide)

Relevant research groups

  • None

Evidence Review Group

  • National Institute for Health Research Health Technology Assessment Programme
  • NHS Centre for Reviews & Dissemination and Centre for Health Economics -York

Associated guideline groups

  • None

Associated public health groups

  • None

Top


 

Project history

Date Update
24 December 2010 On 10 November 2010, the NICE Appraisal Committee met to consider the consultation response received on the preliminary recommendations for the use of golimumab in the treatment of psoriatic arthritis. With the consultation response new evidence was presented that necessitates further clarification from the manufacturer. The Committee will continue consideration of this topic at the 11 January 2011 meeting. No documentation will be issued at this stage.
Top


 

Key documents

This page was last updated: 06 May 2011

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.